Newsletter to Customers
Released
Released
Announcement PDF
3/31/2015
resonancehealth.cmail1.com/t/ViewEmail/t/11DDF32E5685A848
March 2015
No Images? Click here
Welcome to our Quarter 1 newsletter for 2015 which aims to provide customers
with an insight into our activities, service updates and research and development.
Please visit our new website www.resonancehealth.com we would love to hear
your comments at info@resonancehealth.com
Customer Focus: UCL
Heart Hospital Project
Resonance Health was delighted to be invited to
work with Professor James Moon (UCL Heart
Hospital, UK) and his London research group to
design and manufacture MRI phantoms for use
in
a
quantitative
cardiac
T1
imaging
standardisation programme.
Cardiac T1
mapping has applications in cardiac disease
monitoring, including myocarditis, myocardial
oedema, fibrosis, amyloidosis and siderosis.
Approximately 60 phantoms (comprising 12 test
tube solutions which form a set of ‘standards’)
will be manufactured and distributed to leading
cardiac magnetic resonance centres throughout
the world. A central lab at UCLH, London will
use the extensive data generated by the
phantom scanning over the next 12 months to
instigate T1 mapping standardisation.
Andrew Bathgate, Quality Assurance and
Regulatory Affairs Manager at Resonance
Health said:
http://resonancehealth.cmail1.com/t/ViewEmail/t/11DDF32E5685A848
Liver Forum
and EASL,
Vienna
April 2015
Resonance Health will
be attending the 2nd
Liver Forum in Vienna
in April as a prelude to
the
European
Association
of
the
Study of the Liver
(EASL)
conference
which sees around
10,000
delegates
attend each year. The
forum
provides
an
arena for the FDA
clinical
fraternity,
pharmaceutical
and
invited organisations to
hold open discussions
on clinical development
1/5
3/31/2015
resonancehealth.cmail1.com/t/ViewEmail/t/11DDF32E5685A848
We welcome the opportunity to bring our
core lab capabilities and expertise in
clinical studies to this exciting Cardiac T1
mapping project as part of their
and drug
advance
outcomes
disease.
trials to
health
in
liver
standardisation programme. This project
enables us to collaborate with world
leading Cardiac Centres and MRI
manufacturers and to potentially provide
phantoms as well as cardiac T1 mapping
services in future cardiac disease related
multicentre clinical studies.
Chief Scientific Officer
at Resonance Health,
Prof. Tim St Pierre
said:
We look forward to
contributing to the
Liver Forum and
will also present
the latest data on
HepaFatScan® to
the
clinical
community at the
EASL conference.
Please come and visit
our team at exhibition
stand # 440 I where we
will be delighted to
meet you.
SCMR/ISRM Conference Nice, France. Left to
Right: Andrew Bathgate, QA/RA Manager
(Resonance Health) Dr Gabriella Captur (UCL)
holding demonstration phantom, Prof James
Moon, (UCLH), Friso Heslinga (UWA Masters
Student)
Global Access to the Gold
Standard MRI for Liver
Iron Concentration
http://resonancehealth.cmail1.com/t/ViewEmail/t/11DDF32E5685A848
Role of
HepaFatScan
in Liver
Cancer
Surgery
Commencing
this
quarter, the application
of HepaFatScan in
liver cancer surgery will
be investigated. This
Australian based, multi
centre,
randomised
2/5
3/31/2015
resonancehealth.cmail1.com/t/ViewEmail/t/11DDF32E5685A848
Resonance Health continues to strengthen
collaborations with stakeholders from the clinical
and patient communities and is currently
undertaking joint activities with the Pan
European imaging chain, Alliance Medical Ltd in
the UK to provide better access to FerriScan
throughout the country.
As part of an ongoing clinical education
programme FerriScan has also been profiled at
key clinical meetings in Europe, including the
Thalassaemia International Federation (TIF)
Conference in Athens to over 500 delegates.
The updated TIF guidelines are now available
which reference FerriScan (R2MRI) for
monitoring
of
Liver
Iron
Concentration http://www.thalassaemia.org.c
y.
A recent abstract presented at the American
Society of Haematology (ASH) by an Italian
network of hospitals also advocated the crucial
role FerriScan plays in management of
Haemoglobinopathy patients.
https://ash.confex.com/ash/2014/webprogra
m/Paper70043.html
This year, the company will continue to focus on
improving access to FerriScan in countries
where there are large numbers of patients and
limited access to accurate quantitative MRI
measurement of Liver Iron Concentration. In the
last six months FerriScan has become available
in many new countries including most recently
Bulgaria and Romania.
clinical
study
will
involve comparing the
clinical outcomes of
patients with colorectal
metastases
who
receive HepaFatScan
before surgery with
those who do not
receive HepaFatScan.
The study follow up
period will be 6 months
post surgery. The study
aims to help liver
surgeons optimise their
surgical plan, resulting
in
better
clinical
outcomes
for
the
patient(s). Preliminary
results are expected
late 2016.
Team Member
In Focus:
Sander
Bangma
General
Manager
Sander Bangma joined
Resonance Health in
2005 and has recently
been
appointed
New Website and Logos
For Resonance Health
General
Manager.
Born and, raised in the
Resonance Health has completed work on the
redevelopment of our existing website and have
at Utrecht University
before
moving
to
updated our logos. The web pages have a fresh
new look with contemporary design guidelines
Australia.
Master’s
including responsive design, allowing easy
access via portable devices such as tablets and
Computer Science and
completed a Diploma in
http://resonancehealth.cmail1.com/t/ViewEmail/t/11DDF32E5685A848
Netherlands,
he
completed his studies
He holds a
Degree in
3/5
3/31/2015
resonancehealth.cmail1.com/t/ViewEmail/t/11DDF32E5685A848
mobile phones. The new website offers
improved speed and reliability together with up
Management.
Throughout his
todate features and general user friendliness.
with Resonance Health
We look forward to comments and feedback on
the new site from our valued customers.
he has gained a wealth
of experience in the
Please visit us at www.resonancehealth.com
daytoday operations
of
the
Company.
time
Sander previously held
a dual role in the
Company
as
Development Manager
and Service Centre
Manager.
In these
roles his responsibilities
included overseeing all
software
device
medical
development
activities,
IT
infrastructure and the
Company’s Intellectual
Property portfolio, as
well as all facets of
Resonance
analysis
China Delegation
In January, key members from the R&D and
Marketing teams undertook a trip to China to
Health’s
service
provision. He continues
to
hold
overall
continue the commercialisation of both HepaFat
responsibility for these
areas.
In his spare
Scan and FerriScan in the China market. The
team met with Key Opinion Leader’s in hospitals
time he enjoys going
for a bike ride along
around Beijing,
Guangzhou.
Perth’s beautiful Swan
Shanghai,
Nanjing
and
River and taking the
kids to the beach.
Wenjie Pang, Technical and Research Manager
said:
The use of FerriScan and awareness of
the
value
to
the
clinical
community
continues to grow in China and the visit
has been fruitful with strong interest in
HepaFatScan and anticipated trialing to
commence within the year.
http://resonancehealth.cmail1.com/t/ViewEmail/t/11DDF32E5685A848
4/5
3/31/2015
resonancehealth.cmail1.com/t/ViewEmail/t/11DDF32E5685A848
Wenjie Pang and Prof. Yan
Coming Soon
A clinical study in a leading USA hospital is planned to substantiate the role of
HepaFatScan in Non Alcoholic Fatty Liver Disease.
Thalassaemia Meeting May 8th in Palermo will showcase the FerriScan R2
Network ‘LICNET’ led by Prof. Maggio with Prof. Tim St Pierre an invited
speaker.
Continued work on our Fibrosis technology, R&D update next issue.
Resonance Health
TWEET
278 Stirling Highway Claremont WA 6010 Australia
www.resonancehealth.com
FORWARD
You are receiving this email as you are registered in FAST or have
expressed interest in Resonance Health and/or our services
Preferences | Unsubscribe
http://resonancehealth.cmail1.com/t/ViewEmail/t/11DDF32E5685A848
5/5
Share your feedback
Discover